Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?
How US Commercial Payers Will Manage Rapidly Increasing Drug Costs
Executive Summary
Payers cannot control the pricing of new products by biopharmaceutical companies, but their goal is to deliver quality health care in a cost-effective manner. Several payer medical directors representing over 100 million commercially insured members have shared their insights for managing the challenging US market – revealing their thoughts on drug pricing currently, and steps they plan to take in the next 3 to 5 years to better control rising costs.
You may also be interested in...
Vision Healthcare Makes Probiotic Play With AixSwiss Acquisition
European dietary supplements online specialist Vision Healthcare has added the Nupure probiotics brand to its portfolio with the acquisition of Netherlands-based AixSwiss.
Lacutamab Data Boost Prospects For Innate Pharma
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.
Economic Crisis Expected To Shape UK’s Future Drug Pricing Deal
The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines access from 2024 onwards.